Psychae Therapeutics

About

Psychae Therapeutics develops medical-grade, botanically derived psychedelic medicines and provides psychedelic-assisted therapies for PTSD, anxiety, and addiction, collaborating with CSIRO Botanical Extracts Lab to pursue medical registration.

Mission

Psychae Therapeutics is developing medical-grade, botanically derived treatments and psychedelic-assisted therapies to treat serious mental health challenges such as PTSD, anxiety and addiction. The company positions psychedelic therapies as emerging, highly effective, fast-acting and safe treatments for mental disorders and addiction. Co-founded by Associate Professor Daniel Perkins and Professor Jerome Sarris, Psychae is pioneering the field of psychedelic-assisted therapy. It is collaborating with the CSIRO Botanical Extracts Lab and using CSIRO’s research and commercialisation expertise and facilities to develop novel psychedelic medicines. The University of Melbourne announced a $4.5 million syndicated investment from the university’s Genesis Pre-Seed Fund and Tin Alley Ventures to support the startup. The new funding is intended to strengthen the company’s business and research strategy and capabilities to achieve medical registration of botanically derived pharmaceutical-grade medicines for suitable patient cohorts.

Quick Facts